Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization

In some randomized studies, researchers are interested in determining the effect of treatment assignment on outcomes that may exist only in a subset chosen after randomization. For example, in preventative human immunodeficiency virus (HIV) vaccine efficacy trials, it is of interest to determine whether randomization to vaccine affects postinfection outcomes that may be right-censored. Such outcomes in these trials include time from infection diagnosis to initiation of antiretroviral therapy and time from infection diagnosis to acquired immune deficiency syndrome. Here we present sensitivity analysis methods for making causal comparisons on these postinfection outcomes. We focus on estimating the survival causal effect, defined as the difference between probabilities of not yet experiencing the event in the vaccine and placebo arms, conditional on being infected regardless of treatment assignment. This group is referred to as the always-infected principal stratum. Our key assumption is monotonicity—that subjects randomized to the vaccine arm who become infected would have been infected had they been randomized to placebo. We propose nonparametric, semiparametric, and parametric methods for estimating the survival causal effect. We apply these methods to the first Phase III preventative HIV vaccine trial, VaxGen's trial of AIDSVAX B/B.

[1]  B. Graham Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[2]  A. Dawid Causal Inference without Counterfactuals , 2000 .

[3]  D. Rubin [On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9.] Comment: Neyman (1923) and Causal Inference in Experiments and Observational Studies , 1990 .

[4]  James M. Robins,et al.  Causal Inference Without Counterfactuals: Comment , 2000 .

[5]  M. Halloran,et al.  Causal Inference in Infectious Diseases , 1995, Epidemiology.

[6]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[7]  T. VanderWeele Simple relations between principal stratification and direct and indirect effects , 2008 .

[8]  D. Mehrotra,et al.  Eliciting a Counterfactual Sensitivity Parameter , 2007 .

[9]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[10]  Winfried Stute,et al.  The Central Limit Theorem Under Random Censorship , 1995 .

[11]  D. Rubin Comment on "Causal inference without counterfactuals," by Dawid AP , 2000 .

[12]  J. Robins,et al.  Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models , 1999 .

[13]  J. Robins A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .

[14]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[15]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[16]  Roderick J. A. Little,et al.  Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models: Comment , 1999 .

[17]  Donald B. Rubin,et al.  Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .

[18]  M. Hudgens,et al.  Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials , 2003, Biometrics.

[19]  A A Tsiatis,et al.  Causal Inference on the Difference of the Restricted Mean Lifetime Between Two Groups , 2001, Biometrics.

[20]  G. Nabel Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.

[21]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[22]  P. Rosenbaum The Consequences of Adjustment for a Concomitant Variable that Has Been Affected by the Treatment , 1984 .

[23]  Andrea Rotnitzky,et al.  Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials , 2006, Biometrics.

[24]  Michael G Hudgens,et al.  On the analysis of viral load endpoints in HIV vaccine trials , 2003, Statistics in medicine.

[25]  James M. Robins,et al.  An analytic method for randomized trials with informative censoring: Part II , 1995, Lifetime data analysis.

[26]  Michael G Hudgens,et al.  Causal Vaccine Effects on Binary Postinfection Outcomes , 2006, Journal of the American Statistical Association.